Apogee Therapeutics (NASDAQ:APGE) Downgraded to Hold Rating by Citigroup

Posted by Stanley Muller on Jun 23rd, 2026

Citigroup lowered shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) from a strong-buy rating to a hold rating in a research report report published on Monday morning,Zacks.com reports.

Several other research analysts have also recently issued reports on APGE. BTIG Research reiterated a “buy” rating and set a $137.00 target price on shares of Apogee Therapeutics in a report on Wednesday, May 27th. Canaccord Genuity Group restated a “hold” rating and issued a $135.11 price target (up from $130.00) on shares of Apogee Therapeutics in a report on Monday. Guggenheim upped their price target on shares of Apogee Therapeutics from $130.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Rothschild & Co Redburn began coverage on shares of Apogee Therapeutics in a research report on Friday, May 1st. They issued a “buy” rating and a $140.00 price target for the company. Finally, Mizuho increased their price objective on shares of Apogee Therapeutics from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, March 30th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Apogee Therapeutics has an average rating of “Hold” and a consensus target price of $118.08.

Check Out Our Latest Stock Analysis on APGE

Apogee Therapeutics Trading Up 46.7%

Apogee Therapeutics stock opened at $132.55 on Monday. The firm has a 50-day moving average price of $85.82 and a 200-day moving average price of $78.46. The firm has a market capitalization of $8.20 billion, a PE ratio of -30.61 and a beta of 0.62. Apogee Therapeutics has a 12-month low of $34.34 and a 12-month high of $133.00.

Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last issued its earnings results on Monday, May 11th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.01. As a group, sell-side analysts predict that Apogee Therapeutics will post -4.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Carl Dambkowski sold 5,500 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $78.71, for a total value of $432,905.00. Following the transaction, the insider directly owned 205,648 shares of the company’s stock, valued at $16,186,554.08. This represents a 2.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 20,000 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $83.38, for a total value of $1,667,600.00. Following the completion of the transaction, the chief executive officer owned 1,095,987 shares of the company’s stock, valued at $91,383,396.06. This trade represents a 1.79% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 76,500 shares of company stock worth $6,323,295 over the last three months. Corporate insiders own 24.30% of the company’s stock.

Hedge Funds Weigh In On Apogee Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Apogee Therapeutics by 189,522.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,732,456 shares of the company’s stock valued at $206,246,000 after acquiring an additional 2,731,015 shares during the last quarter. Janus Henderson Group PLC lifted its position in Apogee Therapeutics by 324.4% during the fourth quarter. Janus Henderson Group PLC now owns 2,062,604 shares of the company’s stock valued at $155,697,000 after purchasing an additional 1,576,626 shares during the period. Perceptive Advisors LLC lifted its position in Apogee Therapeutics by 72.4% during the fourth quarter. Perceptive Advisors LLC now owns 2,330,651 shares of the company’s stock valued at $175,918,000 after purchasing an additional 978,662 shares during the period. Wellington Management Group LLP boosted its holdings in Apogee Therapeutics by 24.1% in the third quarter. Wellington Management Group LLP now owns 4,723,701 shares of the company’s stock valued at $187,673,000 after purchasing an additional 917,991 shares during the last quarter. Finally, UBS Group AG boosted its holdings in Apogee Therapeutics by 646.1% in the third quarter. UBS Group AG now owns 799,465 shares of the company’s stock valued at $31,763,000 after purchasing an additional 692,308 shares during the last quarter. Institutional investors and hedge funds own 79.04% of the company’s stock.

Key Stories Impacting Apogee Therapeutics

Here are the key news stories impacting Apogee Therapeutics this week:

Positive Sentiment: AbbVie announced a definitive agreement to acquire Apogee Therapeutics in cash, giving shareholders $135.11 per share and creating a clear buyout premium for the stock. AbbVie strikes $10.9 billion deal for Apogee Therapeutics
Positive Sentiment: The deal strengthens AbbVie’s immunology pipeline by adding Apogee’s clinical-stage therapies for inflammatory diseases, which is supporting investor confidence in the transaction closing. AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
Positive Sentiment: Several market reports highlighted Apogee as a top premarket mover and noted the stock surged on the acquisition news, reinforcing that the rally is being driven by the buyout announcement. Stocks making the biggest moves premarket: Apogee Therapeutics, SpaceX, Arcosa & more
Neutral Sentiment: Canaccord Genuity reaffirmed its “hold” rating and raised its price target to $135.11, essentially matching the proposed deal price and suggesting limited upside beyond the acquisition terms. Apogee Therapeutics had its hold rating reaffirmed by Canaccord Genuity Group Inc.
Negative Sentiment: Law firms have begun investigations into whether Apogee shareholders are receiving a fair price, which could create legal noise around the deal process even though it does not change the announced offer. APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

About Apogee Therapeutics

(Get Free Report)

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.